Trials / Approved For Marketing
Approved For MarketingNCT04617002
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- —
Summary
This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONC201 (dordaviprone) | ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist. |
Timeline
- First posted
- 2020-11-05
- Last updated
- 2025-08-20
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04617002. Inclusion in this directory is not an endorsement.